Today, due to the advancement of biotechnology and human pursuit of health, peptide-based drugs have become one of the mainstream drugs for the treatment of various diseases.
This journey began in 1953 with the discovery of oxytocin, the first synthetic peptide-based therapeutic. In 1974, recombinant DNA technology enabled industrialized production of therapeutic peptides, and human insulin was the first approved therapeutic peptide synthesized in this way. Many therapeutic peptides, including natural and synthetic analogs, are undergoing clinical trials.
Our peptidomimetic development technology focuses on the shortcomings of peptide drugs in disease treatment, and various approaches have been designed to enhance peptide stability, such as integrating D-amino acids (increasing protease resistance) or α-aminooxy amino acids, Altering backbone chemistry and cyclization has the ability to provide peptidomimetic-based therapeutic development options for multiple diseases.
Application of Peptidomimetics in Disease Treatment
Peptidomimetic drugs have been widely used in treatments such as urology, respiratory, pain, oncology, metabolism, cardiovascular and antibacterial. To date, more than 170 peptides are in active clinical development and many more are in preclinical research. Follow our drug screening service to learn more about the development and screening of peptidomimetic drugs for various types of diseases.
As Therapeutic Drugs
Over the years, peptides have developed into promising therapeutics for the treatment of cancer, diabetes, and cardiovascular disease, and their applications in various other therapeutic areas are rapidly growing. There are currently about 60 approved peptide drugs on the market, with annual sales exceeding $13 billion. The number of peptide drugs entering clinical trials has steadily increased; there are hundreds of candidate peptides in clinical and preclinical development; since 2000, peptides entering clinical research are most commonly used for the adaptation of cancer (18%) and metabolic disorders (17%) disease.
As Drug Carriers
A variety of peptide receptors in organisms are known to serve as potential drug targets in disease treatment. The developed peptides can be combined with cytotoxic or biologically active substances to deliver them to target cells expressing the corresponding peptide receptors. For example, one potential drug candidate, AEZS-108, conjugates the peptide LHRH to the chemotherapeutic agent doxorubicin to directly target cells expressing the LH-RH receptor for the treatment of prostate cancer. To date, the development of targeted peptidomimetic carriers provides a good platform for the cell-specific delivery of these chemotherapeutic agents.
As Vaccines
Over the past decade, the idea of peptide vaccination against cancer has been translated into clinical research, and this approach to treating cancer cells relies on vaccines consisting of peptides derived from the protein sequences of candidate tumor-associated or specific antigens. Several peptide vaccines have been tested in clinical trials, such as HPV-16 E7 peptide, Ras oncoprotein peptide. Peptide vaccines are relatively inexpensive, easy to manufacture and operate, and synthetic in nature. The main disadvantage of peptide vaccines is that they are less immunogenic. The development of peptidomimetics to enhance peptide immunogenicity and efficacy is therefore a very effective strategy.
As Diagnostic Tools
Based on the latest research findings, peptides have important application value in disease diagnosis and screening, and the most concerned is the application in the detection of new coronary pneumonia. Major pharmaceutical companies around the world are actively developing antigen detection kits, of which the development of targeted peptides for the structural proteins of the new coronavirus for rapid detection has achieved great success. In addition, peptide probes, peptide microarrays and chips developed based on the principles of immunology have also been widely used in early disease screening tests. On this basis, peptidomimetics overcome some inherent defects of peptides and will achieve better application effects.
CD BioSciences is committed to the development of high-throughput peptidomimetics, which are widely used in the field of disease treatment. If you have any application or service you want to know about, please do not hesitate to contact us immediately for the best advice and solutions.
References
- Thundimadathil, J. (2012). Cancer Treatment Using Peptides: Current Therapies and Future Prospects. Journal of Amino Acids, 2012, 1-13.
- Baig, M. H., Ahmad, K., Saeed, M., Alharbi, A. M., Barreto, G. E., Ashraf, G. M., & Choi, I. (2018). Peptide based therapeutics and their use for the treatment of neurodegenerative and other diseases. Biomedicine & Pharmacotherapy, 103, 574-581.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
